Devyser Diagnostics AB (OL0)
Market Closed
17 Aug, 20:00
XDUS €
5. 45
-0.23
-4.0493%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
-0.31 Eps
€ 5.68
Previous Close Want to track OL0 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
OL0 closed today lower at €5.45, a decrease of -4.0493% from yesterday's close, completing a monthly decrease of -28.7582% or -€2.2. Over the past 12 months, OL0 stock lost -48.1939%.
OL0 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on XMUN (EUR).
OL0 Chart
Devyser Diagnostics AB (OL0) FAQ
What is the stock price today?
The current price is €5.45.
On which exchange is it traded?
Devyser Diagnostics AB is listed on XDUS.
What is its stock symbol?
The ticker symbol is OL0.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Devyser Diagnostics AB ever had a stock split?
No, there has never been a stock split.
Devyser Diagnostics AB Profile
| Professional Services Industry | Industrials Sector | Mr. Jan Wahlstrom CEO | XDUS Exchange | - ISIN |
| SE Country | 110 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Devyser Diagnostics AB (publ), established in 2004 and headquartered in Hägersten, Sweden, specializes in the development and provision of diagnostic kits and solutions. The company's focus is primarily on DNA testing for hereditary diseases, oncology, and the monitoring of patients post-transplantation. Serving a global market, Devyser extends its reach across Sweden, the rest of Europe, the Middle East, Africa, North and South America, and Asia. Its commitment to innovation and quality in diagnostics propels its mission to enable targeted cancer treatments, diagnose genetic diseases, and assist in the follow-up of transplant patients.
Products and Services
Devyser Diagnostics offers a diverse portfolio of products and services across various medical and genetic testing fields:
- Post-Transplantation: Diagnostic solutions designed for the follow-up of transplant patients, ensuring the early detection of potential complications and the efficient monitoring of organ acceptance.
- Thalassemia: Tests specifically developed for the identification and characterization of thalassemias, a group of genetic blood disorders, facilitating accurate diagnosis and management.
- Breast and Ovarian Cancer: Diagnostic kits for the genetic predisposition testing of breast and ovarian cancer, aiding in early detection and personalized treatment plans.
- Non-invasive fetal RHD Screening Prenatal Testing: Advanced prenatal testing solutions for the non-invasive determination of fetal Rhesus D (RhD) status, improving pregnancy management and reducing unnecessary interventions.
- Hereditary Diseases: Comprehensive testing kits for a wide range of genetic diseases, supporting the diagnosis and understanding of hereditary conditions.
- Cystic Fibrosis: Specific diagnostic tools for cystic fibrosis, facilitating early detection and allowing for tailored therapeutic strategies.
- Cardiovascular: Diagnostic assays aimed at identifying genetic markers associated with cardiovascular diseases, contributing to risk assessment and personalized medicine.
- Male Infertility: Tests developed to uncover genetic causes of male infertility, assisting in diagnosis and the guidance of treatment options.
- Rapid Aneuploidy Analysis: Fast and reliable solutions for the analysis of chromosomal aneuploidies, important for prenatal diagnosis and fertility treatments.
- Accessories: A selection of complementary products and accessories that support the effective use and application of Devyser's diagnostic kits.
Contact Information
Address: Bränningevägen 12, Årsta, Sweden, 120 54
Phone: 46 8 56 21 58 50
Website: https://devyser.com
